COSTA MESA, Calif. (PRWEB) January 18, 2008
Virulite, LLC has validated the US market for the Virulite device by successfully completing clinical trials and is presently in the process of obtaining FDA clearance. The Virulite product is successful in the UK and is both approved by the British National Health Service and CE marked.
The Virulite product, (patents granted and pending), is a portable, hand held device that uses an invisible, non-thermal band of near-infrared light. Virulite was developed in the UK after ten years of research and development, and has been medically proven in independent clinical trials to reduce the healing time of cold cores by up to one half.
The company completed a US market test of the product through Walgreen's online distribution channel, where Virulite outsold all competing cold sore remedies, including the current market leader, the topical cream Abreva by GlaxoSmithKline (GSK). In addition, Virulite received numerous customer testimonials from users who experienced astonishing results. Virulite, LLC recognizes the product requires a home with an established pharmaceutical, health product or medical device company in order to effectively penetrate the estimated $4 billion cold sore remedy market, and is actively seeking suitors.
About Virulite, LLC
Virulite LLC is focused on developing consumer markets using the Virulite 1072 nanometer technology. While the cold sore treatment is proven, the technology also has shown anecdotal success in treating genital herpes, bacterial infections and warts (clinical trials are underway for the latter two). For more information, visit http://www.virulite.com
About Compass Point Capital, Inc. and Murphy Business and Financial Corporation
Compass Point is a leading west coast mergers and acquisition firm specializing in middle market companies and will be working with Murphy Business, one of the largest business sales organizations with offices nationwide. For more information, visit http://www.compasspointcapital.com and http://www.murphybusiness.com